CD90 Polyclonal Antibody bs-20640R from Bioss Inc.

Published Figures

Register or Sign In to View Figures.

Bioactive materials
January 01 0001

Fig 1: DBM-MSN/152RM scaffolds coordinate the recruitment of MSCs and ECs in vivo. (A) HE staining images demonstrating the recruitment of MSCs and ECs 1 week after DBM, DBM-MSN, DBM/152RM and DBM-MSN/152RM scaffold implantation (n = 5 rats per group). Scale bar, 100 μm. (B) Co-immunofluorescence staining of CXCR4, integrin αvβ3 and CD271 in MSCs from 1 week after DBM, DBM-MSN, DBM/152RM and DBM-MSN/152RM scaffold implantation (n = 5 rats per group). Scale bar, 100 μm. (C) Immunofluorescence staining of CD90+CD105+ MSCs from 1 week after DBM, DBM-MSN, DBM/152RM and DBM-MSN/152RM scaffold implantation (n = 5 rats per group). Scale bar, 100 μm. (D) Co-immunofluorescence staining of emcn and integrin αvβ3 in type H vessels from 4 weeks after DBM, DBM-MSN, DBM/152RM and DBM-MSN/152RM scaffold implantation (n = 5 rats per group). Scale bar, 100 μm. (E) Immunofluorescence staining of CD31+ in EPCs from 4 weeks after DBM, DBM-MSN, DBM/152RM and DBM-MSN/152RM scaffold implantation (n = 5 rats per group). Scale bar, 100 μm. Data are shown as the mean ± SD. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001; ANOVA was employed. For all panels in this figure, data are representative of three independent experiments.
Register or Sign In to View Figures.

International Dental Journal
August 01 2026

Fig 2: Sal pretreatment promotes the viability and migration of hDPSCs after OGD. A, hDPSCs showing negative expression of CD34 (200×, scale bar = 50 μm). B, hDPSCs showing positive expression of CD90 (200×, scale bar = 50 μm). C, hDPSCs showing positive expression of CD146 (200×, scale bar = 50 μm). D, Viability of hDPSCs treated with different concentrations of Sal, assessed by CCK-8 assay (n = 3). E, Viability of hDPSCs pretreated with different concentrations of Sal for 48 hours and then cultured with or without OGD, measured by CCK-8 assay (n = 6). F, Quantitative analysis of the migratory capacity of hDPSCs pretreated with different concentrations of Sal for 48 hours and then cultured with or without OGD, assessed by scratch assay. Migration percentage is calculated relative to the initial wound area (n = 3). G, Representative fluorescence images (Calcein AM staining) of hDPSC migration at 0, 24 and 48 hours after scratch wounding under the conditions described in (F) (40×, scale bar = 200 μm). ***P < .001, **P < .01, *P < .05.

Be the first to write a review!

Citations:

(2)

Figures:

Supplier Page

Supplier Page from
Bioss Inc. for
CD90 Polyclonal Antibody

Bioss Inc.'s CD90 Polyclonal Antibody is a Rabbit Polyclonal antibody. This antibody has been shown to work in applications such as: Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Immunohistochemistry - fixed, and Immunohistochemistry - frozen. The CD90 Polyclonal Antibody was generated using Thy1 as the antigen and it reacts with Mouse.

Description

Thy-1 or CD90 (Cluster of Differentiation 90) is a 2537 kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored conserved cell surface protein with a single V-like immunoglobulin domain, originally discovered as a thymocyte antigen. Thy-1can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Structural study of Thy-1 lead to the foundation of the Immunoglobulin superfamily, of which it is the smallest member, and led to some of the initial biochemical description and characterization of a vertebrate GPI anchor and also the first demonstration of tissue specific differential glycosylation

Bioactive materials

International Dental Journal

CD90 Polyclonal Antibody from Bioss Inc.

Description

Bioss Inc.

Citations (2)

Reviews

CD90 Polyclonal Antibody from Bioss Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map